U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16FN3O2S.C4H4O4
Molecular Weight 461.463
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of VONOPRAZAN FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CC=CN=C3

InChI

InChIKey=ROGSHYHKHPCCJW-WLHGVMLRSA-N
InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C17H16FN3O2S
Molecular Weight 345.391
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25744862| https://www.ncbi.nlm.nih.gov/pubmed/20624992

Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.003 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TAKECAB

Approved Use

Unknown
Curative
TAKECAB

Approved Use

Unknown
Curative
TAKECAB

Approved Use

Unknown
Primary
TAKECAB

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
2010 Oct
Patents

Sample Use Guides

Orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.
Route of Administration: Oral
TAK-438 (Vonoprazan) inhibited H(+),K(+)-ATPase activity in porcine gastric microsomes with IC(50) values of 0.019 μM at pH 6.5. The inhibitory activity of TAK-438 was unaffected by ambient pH. The inhibition by TAK-438 was reversible and achieved in a K(+)-competitive manner.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:55:11 GMT 2023
Edited
by admin
on Sat Dec 16 01:55:11 GMT 2023
Record UNII
4QW3X4AMLB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VONOPRAZAN FUMARATE
Common Name English
TAK-438
Code English
VOCINTI
Brand Name English
VONOPRAZAN MONOFUMARATE
Common Name English
VONOPRAZAN FUMARATE [JAN]
Common Name English
VOQUEZNA
Brand Name English
1H-PYRROLE-3-METHANAMINE, 5-(2-FLUOROPHENYL)-N-METHYL-1-(3-PYRIDINYLSULFONYL)-, (2E)-2-BUTENEDIOATE (1:1)
Systematic Name English
TAKECAB
Brand Name English
TAK 438
Common Name English
VONOPRAZAN FUMARATE [MI]
Common Name English
TAK-438 MONOFUMARATE
Code English
Vonoprazan fumarate [WHO-DD]
Common Name English
Code System Code Type Description
RXCUI
2604576
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
EVMPD
SUB181653
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
FDA UNII
4QW3X4AMLB
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
DAILYMED
4QW3X4AMLB
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
EVMPD
SUB88193
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
CAS
1260141-27-2
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
SMS_ID
100000139518
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
CAS
881681-01-2
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
PUBCHEM
45375887
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
MERCK INDEX
m11860
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
NCI_THESAURUS
C151949
Created by admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY